申请人:Medivir AB
公开号:US06291687B1
公开(公告)日:2001-09-18
Compounds of the formula I:
wherein:
A′ and A″ are independently the same or different group of the formula II:
wherein:
R′ is H. CH3, C(CH3)2, —ORa, —N(Ra)2, —N(Ra)ORa or —DP
R′″ is H or CH3; Ra is H, C1-C3 alkyl;
D is a bond, alkylene, —C(═O)—, —S(O)— or —S(O)2—;
P is an optionally substituted, mono or bicyclic carbo- or heterocycle;
R″ is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH2)nDP;
M is a bond or —C(═O)N(R′″)—;
Q is absent, a bond, —CH(OH)— or —CH2—;
or R″ together with Q , M and R′ define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring;
with the proviso that R′ is —ORa, —N(Ra)2, —N(Ra)ORa or —DP, if M is a bond and Q is absent;
X is H, OH, OCH3;
Y is H, OH, OCH3, but X and Y are not both H;
Z′ and Z″ are independently —(CH2)mP where P is as defined above;
n and m are independently 0,1 or 2;
and pharmaceutically acceptable salts and prodrugs thereof have utility as aspartyl protease inhibitors of HIV. They can be prepared in a facile two step synthesis from novel 2,5-di-O-benzyl-L-maannaro-1,4:6,3 dilactone intermediates.
公式I的化合物:其中:A′和A″分别是公式II的相同或不同基团:其中:R′为H、CH3、C(CH3)2、—ORa、—N(Ra)2、—N(Ra)ORa或—DPR′″为H或CH3;Ra为H、C1-C3烷基;D为键、烷基、—C(═O)—、—S(O)—或—S(O)2—;P为可选取代的、单环或双环碳氢或杂环;R″为H、天然氨基酸中发现的任何侧链、羧基乙酰胺或(CH2)nDP群;M为键或—C(═O)N(R′″)—;Q为不存在、键、—CH(OH)—或—CH2—;或者R″与Q、M和R′一起定义一个可选取代的5或6成员碳氢或杂环,该环可选地与另一个5或6成员碳氢或杂环融合;但R′为—ORa、—N(Ra)2、—N(Ra)ORa或—DP,如果M为键且Q不存在;X为H、OH、OCH3;Y为H、OH、OCH3,但X和Y不能同时为H;Z′和Z″独立地为—(CH2)mP,其中P如上定义;n和m独立地为0、1或2;以及其药学上可接受的盐和前药作为HIV的天冬氨酸蛋白酶抑制剂具有实用性。它们可以从新型2,5-二-O-苄基-L-甘露糖-1,4:6,3-二内酯中间体中方便地进行两步合成。